MedTrace Logo

ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features

NCT04825691 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-04-01

No results posted yet for this study

Summary

Evaluation the ERG expression in prostatic acinar adenocarcinoma and its association with clinicopathological features.

Conditions

  • Prostate Adenocarcinoma

Interventions

DIAGNOSTIC_TEST

Immunohistochemistry of prostate biopsy

Sections of formalin fixed paraffin embedded tissue blocks will be stained with ERG oncoprotein. Antibody dilution, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-04
Primary Completion
2022-12-30
Completion
2023-05-23

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04825691 on ClinicalTrials.gov